Amneal Pharmaceuticals/$AMRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Amneal Pharmaceuticals

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Ticker

$AMRX
Primary listing

Industry

Pharmaceuticals

Employees

8,300

ISIN

US03168L1052

AMRX Metrics

BasicAdvanced
$2.5B
-
-$0.04
1.17
-

What the Analysts think about AMRX

Analyst ratings (Buy, Hold, Sell) for Amneal Pharmaceuticals stock.

Bulls say / Bears say

Amneal Pharmaceuticals reported an 18% revenue growth in Q4 2024 and set an ambitious $3 billion revenue target for 2025, indicating strong financial performance and growth prospects. (stocktitan.net)
The company received FDA approval for BORUZU™, the first ready-to-use version of bortezomib for subcutaneous administration, enhancing its oncology portfolio and market competitiveness. (stocktitan.net)
Analysts have expressed positive sentiments, with Truist Financial raising the price target to $12.00 and maintaining a 'buy' rating, reflecting confidence in the company's future performance. (marketbeat.com)
Amneal's debt-to-equity ratio stands at 139.05, surpassing industry norms and indicating potential financial challenges due to substantial debt levels. (markets.businessinsider.com)
The company's Return on Equity (ROE) is -56.27%, suggesting difficulties in maximizing returns on equity capital and potential hurdles in achieving optimal financial performance. (markets.businessinsider.com)
Amneal's net margin is -15.99%, reflecting challenges in profitability and effective cost management compared to industry averages. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

AMRX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AMRX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AMRX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs